- Report
- March 2024
- 191 Pages
Global
From €3242EUR$3,374USD£2,772GBP
€3602EUR$3,749USD£3,080GBP
- Report
- May 2024
- 182 Pages
Global
From €4756EUR$4,950USD£4,066GBP
- Report
- August 2023
- 145 Pages
Global
From €3027EUR$3,150USD£2,588GBP
- Report
- February 2023
- 123 Pages
Global
From €5285EUR$5,500USD£4,518GBP
- Report
- March 2021
- 230 Pages
Global
From €2306EUR$2,400USD£1,972GBP
- Report
- January 2023
- 242 Pages
Global
From €4756EUR$4,950USD£4,066GBP
- Report
- January 2024
- 87 Pages
Global
From €3500EUR$3,902USD£3,097GBP
- Report
- March 2024
- 132 Pages
Global
From €913EUR$950USD£780GBP
The Biologics Safety Testing market is a subset of the biopharmaceuticals industry, which focuses on the development and production of biological drugs. These drugs are derived from living organisms, such as bacteria, viruses, and other cells, and are used to treat a variety of diseases. Biologics Safety Testing is a critical step in the development of these drugs, as it ensures that the drug is safe for human use. This testing involves assessing the safety of the drug in terms of its toxicity, immunogenicity, and efficacy. It also involves assessing the stability of the drug, as well as its ability to be stored and transported.
Companies in the Biologics Safety Testing market include Charles River Laboratories, Eurofins Scientific, SGS, WuXi AppTec, and BioReliance. Show Less Read more
